ESKETAMINE

Brand name:

• Spravato®

Pharmaceutical company:

JANSSEN-CILAG PTY LTD

Condition/indication:
(therapeutic use)

• Treatment resistant depression

PBAC Submission type:

Matters Outstanding (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – December 2024

Related medicines:

• ESKETAMINE

Submission received for:

December 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 13/12/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

20/01/2025

Lodgement of required documentation:

28/01/2025

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 03/02/2025

Status:

Finalised

Government processes:

Commenced on 04/02/2025

Medicine listed on the PBS:

01/05/2025 (see PBS schedule)

---